JACC Author Interviews

Dr. Aaysha Cader, Social Media editor for JACC Interventions and Dr. Chao Gao discuss the pre-specified subgroup analysis of the REC-CAGEFREE I trial: Drug-Coated Balloon Angioplasty vs Drug-Eluting Stents in Noncomplex Coronary Bifurcation Lesions.

Dr. Aaysha Cader, Social Media editor for JACC Interventions and Dr. Antoinette Neylon discuss the randomised KISS trial: Side Branch Additional Treatment for Coronary Bifurcation Lesion Revascularization.

Join us for the latest Behind the Science discussion, featuring an article published in JACC's May 12 focus issue on hypertension. Adith Arun, MD, joins author William B. White, MD, as they discuss a phase 2 randomized trial of the NPR1 agonist XXB750 in patients with resistant hypertension. The interview highlights the study, a randomized, double-blind, placebo-controlled trial of 4 doses of XXB750, administered once-monthly by subcutaneous injection in 189 patients with resistant hypertension. Dose-related changes in cyclic GMP were observed, supporting target engagement of XXB750 at the NPR-1 receptor. However, there was no dose-response pattern observed with respect to change from baseline in 24-hour systolic BP after 12 weeks; none of the doses of XXB750 had a greater BP lowering effect than placebo. #jacc #jaccjournals #behindthescience

In this interview in JACC's May 12 issue focusing on hypertension, JACC Editor-in-Chief Harlan M. Krumholz, MD, SM, MACC speaks with first author Samantha S. O'Connell, MS, MD, as they discuss a comprehensive global analysis of hypertension trends from 2000 to 2020, drawing on data from nearly 300 population-based studies across 119 countries. The findings show that while awareness and treatment have improved modestly—especially in high-income countries—the global burden of hypertension has grown to 1.7 billion adults, with most uncontrolled cases now concentrated in low- and middle-income countries. The conversation emphasizes widening disparities, persistently low control rates, and the urgent need to implement proven strategies worldwide.

Can artificial intelligence really adjudicate heart attacks, strokes, and cardiovascular deaths in clinical trials? Adith Arun sits down with Jonathan W. Cunningham to discuss cutting-edge research using AI to automate major adverse cardiovascular event (MACE) adjudication—one of the most expensive and time‑consuming parts of global clinical trials. They explore how AI models review extensive medical records, assess uncertainty, and work alongside physicians in a hybrid approach that can preserve accuracy while improving efficiency and scalability in large trials.

At ACC.26, JACC Editor-in-Chief Dr. Harlan Krumholz speaks with Dr. Wayne Batchelor about the ALERT Trial, published in JACC. Their discussion explores how automated EHR-based clinician alerts can help identify patients with significant valvular heart disease who may otherwise be overlooked, improving timely referral, heart team evaluation, and valve intervention. The conversation also covers the trial's rigorous cluster-randomized design, the promise of low-cost digital interventions at scale, and important considerations around workflow integration, equity, and implementation across health systems.

In a panel at ACC.26, this video features Dr. Clyde Yancy of Northwestern University in conversation with Ambarish Pandey, Lauren Eberly, Jennifer Cluett, and Oluwabunmi Ogugngbe, exploring how social determinants of health can be studied as measurable variables in clinical research. The discussion highlights innovative trials examining "food as medicine," community-based nutrition interventions, and direct financial support for patients with cardiovascular disease. Through examples involving Indigenous, African American, and socioeconomically disadvantaged populations, the speakers emphasize the importance of trust, community engagement, and culturally tailored approaches. The video underscores a shift toward integrating social factors into cardiovascular science to reduce disparities and improve real-world health outcomes.

Recorded on the final day of ACC.26, this video features an unscripted conversation between Dr. Ami Bhatt, Chief Innovation Officer at the American College of Cardiology, and Dr. Harlan Krumholz, Editor-in-Chief of JACC. They reflect on the rapid expansion of artificial intelligence in cardiology, discussing its impact on clinical workflows, research, education, guideline development, and patient empowerment. The discussion explores ethical considerations, trust, human–AI interaction, and the need for clinicians to actively shape AI's role in healthcare. The video highlights both the opportunities and challenges AI presents, emphasizing collaboration, transparency, and clinician leadership as cardiology enters a transformative era.

Midventricular obstruction in hypertrophic cardiomyopathy (HCM) is rare—but clinically significant. In this episode of Behind the Science, Adith Arun and Alexander Schulz, MD break down new JACC findings showing why midventricular obstructive HCM should be recognized as a distinct, higher‑risk phenotype, rather than grouped with non‑obstructive disease. Through a focused discussion of echocardiographic criteria, intraventricular gradient assessment, Kaplan–Meier outcomes, heart failure risk, and sudden cardiac death signals, the authors explore how midventricular obstruction compares with classic LVOT obstruction—and why current phenotyping may be missing patients. The conversation also examines the implications for cardiac myosin inhibitors, ongoing clinical trials, and the potential value of targeted subgroup analyses to guide future therapy. Essential viewing for cardiologists managing HCM, particularly those interested in advanced imaging, risk stratification, and emerging treatments.

JACC is pleased to present an interview focusing on two papers presented at CRT. Listen in to JACC Executive Associate Editor Karthik Murugiah, MD, FACC, speak with authors Martin Frydland, MD, PhD, and Helle Søholm, MD, PhD, on their paired DOBERMANN-D and DOBERMANN-T trial research. The trials tested early low-dose dobutamine and the IL 6 inhibitor tocilizumab in high-risk STEMI patients to prevent progression to cardiogenic shock. The studies found no difference in the primary outcome (peak NT proBNP), but demonstrated feasibility and safety, with a transient reduction in NT proBNP at 12 hours in the tocilizumab arm, helping inform the design of future prevention-focused shock trials.

In this author interview, JACC Associate Editor Seng Chan You, MD, speaks with Bamba Gaye, MD, PhD, about his team's newly published study examining African representation in randomized clinical trials (RCTs) across major general medical and cardiovascular journals from 2019–2024. Listen in to this behind-the-scenes analysis of this important study addressing the profound underrepresentation of Africa-based trials.

In this featured JACC article, author Naveed Sattar, MD, speaks with deputy editor Erica Spatz, MD, MHS, FACC on how to design trials for the increasing field of obesity medicines. Listen in as they discuss a roadmap for next generation cardiometabolic outcome trials in obesity, emphasizing the need to move beyond traditional MACE focused endpoints toward broader, patient centered outcomes. The interview highlights evolving trial designs, including expanded endpoints, comparisons of placebo versus active controls, and strategies that better reflect real world risk, multimorbidity, and what ultimately matters most to patients.

On Behind the Science, host Adith Arun interviews Dr. Rishi Wadhera and Dr. Sanket Dhruva, lead authors of the new JACC Stats Cardiovascular Statistics Report. They discuss why the report was created, what the latest data reveal about hypertension, diabetes, obesity, and cardiometabolic risk, and why younger adults are facing rising cardiovascular burdens. The conversation also explores geographic disparities, access-to-care challenges, and the implementation gaps that keep proven therapies from reaching patients.

In this episode of Behind the Science, Adith Arun sits down with Rishi Shah to uncover the surprising realities behind new JACC data reports on U.S. cardiovascular health. They break down why major gaps in exercise, sleep, medication adherence, and access still persist—despite gains in insurance coverage. Using NHIS data from 2019–2024, Adith and Rishi explore the stubborn income driven disparities shaping ASCVD risk and discuss what it will take to finally improve cardiovascular equity. A must watch for anyone focused on heart health, population data, or the future of cardiology.

In this ACHD Guideline Spotlight interview, author Curt J. Daniels, MD, and JACC Consultant Anitra W. Romfh, MD discuss the growing adult congenital heart disease population in the U.S., projected to exceed 2 million by 2050. His viewpoint, published in JACC's February 24 issue, highlights the urgent need for more providers, comprehensive care centers, and innovative models like hub-and-spoke networks and telehealth to improve access and outcomes. The conversation also underscores the role of guidelines and collaboration in delivering high-quality, team-based care for this complex patient population.

On February 24, JACC's mini spotlight issue brings readers a focused look on the ACHD guideline. This interview with JACC Consultant Yuli Y. Kim, MD, interviewing authors Babar S. Hasan MBBS and Raman Krishna Kumar MD, DM, takes a look at adapting care for patients with ACHD in low to middle income countries. What do clinicians do in a healthcare environment where diagnostic imaging, advanced interventional cardiology, electrophysiology expertise, multidisciplinary teams, and structured transition programs are not readily available. Although the principles in the guideline shape excellent care in high-income countries, their direct application in low and middle income countries present considerable challenges.

JACC's February 24 issue highlights the ACC/AHA ACHD guideline. In this in-depth interview, JACC Executive Associate Editor Emily Bucholz, MD, PhD, MPH, speaks with JACC Associate Editor Anne Marie Valente, MD, FACC, on her piece co-written with Carole A. Warnes, MD, FACC. In the interview and viewpoint, they discuss key updates in the adult congenital heart disease guidelines, emphasizing expanded evidence, stronger collaboration between ACHD specialists and general cardiologists, and the need for lifelong, multidisciplinary care. What is in store for multicenter research, genetics, and emerging technologies, and how will they shape ACHD care over the next decade?

JACC's February 24 issue is a mini-spotlight issue on the ACHD Guidelines. In this discussion, Lidija B. McGrath, MD, provides additional early career perspective on the 2025 Adult Congenital Heart Disease (ACHD) guidelines. In the interview with JACC Consultant Carla P. Rodriguez-Monserrate, MD, they highlight the value of the guideline as a practical decision aid for clinical care, education, and shared decision making. They discuss key updates including expanded anatomic physiologic classification, greater alignment with real world systems of care, and an increased emphasis on transition, equity, and collaboration with non ACHD specialists. The conversation underscores how the updated guidelines are designed to support clinicians across diverse practice settings while improving care for a growing and complex ACHD population.

Early diagnosis in transthyretin cardiac amyloidosis (ATTR CM) matters more than ever. Adith Arun talks with Dr. Ahmad Masri about key findings from the ATTRIBUTE CM phase 3 trial on acoramidis, what recurrent event analyses reveal, and why delays in suspicion, diagnosis, or treatment can meaningfully impact outcomes. They also explore challenges in clinical pathways, updates in the therapeutic landscape, and the biggest unmet needs as patients live longer with disease directed therapy.

Learn more about the ACHD guideline in JACC's February 24 issue. In our latest interview, JACC Consultant Yonatan Buber, MD, FACC joins author Patrick T O'Gara, MD, MACC to discuss key insights from the 2025 Adult Congenital Heart Disease guidelines and how they intersect with the 2020 ACC/AHA Valvular Heart Disease guidelines. The conversation highlights the importance of multidisciplinary, shared decision-making for younger ACHD patients, particularly when valve interventions have lifelong implications. They also explore how clinicians can thoughtfully navigate between guidelines, balance limited evidence with expert consensus, and refer patients to experienced ACHD centers to optimize long-term outcomes.

The ACHD Guideline gets expert perspectives in JACC's February 24 mini-focus issue. In this interview, join JACC Consultant Sitaram M. Emani, MD, speak with commentary author Emile A. Bacha, MD, FACC, about the maturation of the Adult Congenital Heart Disease (ACHD) specialty following the release of new AHA/ACC guidelines. Dr. Bacha emphasizes the necessity of a multidisciplinary "team sport" approach to care and highlights critical updates regarding earlier surgical intervention, the management of complex Fontan patients, and the treatment of vascular rings. The conversation also addresses the current shortage of ACHD specialists and the evolving nature of the field as new cohorts of complex pediatric survivors transition into adult care.

JACC's February 17 issue gives readers a comprehensive focus issue on women's cardiovascular health, a long overlooked field of study. In this interview, JACC Associate Editor Makoto Mori, MD, joins resident Catherine M. Wagner, MD, MSc, to discuss her brief report on sex differences in tricuspid valve repair during mitral surgery, highlighting that women with moderate or severe tricuspid regurgitation are less likely than men to receive concomitant repair. The findings suggest that reliance on an absolute annular size threshold rather than an indexed threshold may contribute to undertreatment of women, as indexed measurements better reflect disease severity in smaller body sizes. The study emphasizes the need to move toward personalized, indexed criteria in surgical guidelines to reduce care gaps and improve outcomes for women.

In JACC's February 17 issue on Women's Heart Health. JACC Deputy Editor Erica Spatz, MD, joins author and JACC Associate Editor Michael Honigberg, MD, FACC, to discuss the need to rethink cholesterol management in women by moving beyond short term, age driven risk calculators toward a life course approach that accounts for cumulative exposure to atherogenic lipoproteins. His piece in our focus issue highlights opportunities for earlier, individualized prevention—including shared decision making around statin therapy and careful consideration of reproductive goals—to better reduce long term cardiovascular risk in women.

Early diagnosis in transthyretin cardiac amyloidosis (ATTR-CM) matters more than ever. Adith Arun talks with Dr. Ahmad Masri about key findings from the ATTRIBUTE-CM phase 3 trial on acoramidis, what recurrent event analyses reveal, and why delays in suspicion, diagnosis, or treatment can meaningfully impact outcomes. They also explore challenges in clinical pathways, updates in the therapeutic landscape, and the biggest unmet needs as patients live longer with disease-directed therapy.

JACC is pleased to publish this study from authors Nicole J. van Steijn, MD and Michiel M. Winter MD, PhD, featuring the results of integrating Apple Watch monitoring into a clinical workflow. In this video interview accompanying the article,  JACC: Associate Editor Xiaoxi Yao, PhD, MPH, MS  joins first author Nicole van Steijn, MD, to discuss how findings led to a fourfold increase in early atrial fibrillation detection among high risk patients. Timely ECG review within an established e health program enabled rapid diagnosis and highlights the importance of infrastructure and reimbursement for scalable use of wearable technologies. The conversation explores how consumer wearables may play an expanding role in AF screening, stroke prevention, and future cardiovascular care.

This JACC Author Interview features  Karen Joynt Maddox, MD, MPH, and JACC Executive Associate Editor Mitsuaki Sawano, MD, discussing this paper published in the March 24 issue of JACC. The paper looks into cardiovascular care and outcomes among Medicare beneficiaries during the late phase of the COVID-19 pandemic (2021–2022). The research reveals persistent reductions in hospitalizations, increased outpatient visits driven by telehealth, and a concerning 20% rise in mortality—especially among socially vulnerable populations and Medicare Advantage enrollees. In this in-depth author interview, learn about potential biological, behavioral, and systemic factors behind these trends and the importance of strengthening healthcare resilience for future crises. #jacc #jaccjournals

In this episode of Behind the Science, Adith Arun, BS, speaks with Paul Lacaze, PhD, and Sultana Monira Hussain, PhD about their study in JACC's January 6 issue, examining loss of the Y chromosome (LOY) in older men and its association with cardiovascular disease. They discuss the study design, analytical approach, and key findings linking LOY to an increased risk of major adverse cardiovascular events, particularly myocardial infarction. The conversation explores potential biological mechanisms underlying these associations, the strengths and limitations of the data, and how LOY could emerge as a novel biomarker for cardiovascular risk stratification in men. The episode also looks ahead to future research directions and possible clinical applications. #jacc #jaccjournals #behindthescience

In this episode of Behind the Science, Adith Arun and Dr. Neal K Lakdawala discuss the recent phase 2A trial of Danicamtiv in patients with dilated cardiomyopathy (DCM). They explore the study's design, patient cohorts, clinical implications, and the importance of genetic testing and patient-reported outcomes. The conversation also touches on the future of gene therapy in cardiomyopathy and ongoing studies like Kinship DCM. Takeaways: The trial tested a myosin activator to improve cardiac function. Patients with sarcomeric dysfunction may benefit most from Danicamtiv. LVEF improvements varied across genetic cohorts in the study. Clinical thresholds for treatment response are crucial in rare diseases. Patient-reported outcomes like KCCQ are essential for assessing treatment efficacy. Genetic testing for DCM is underutilized in clinical practice. Gene therapy is emerging as a potential treatment for cardiomyopathy. The Kinship DCM study aims to further investigate Danocamtiv's effects. Understanding differential efficacy and toxicity is vital for future treatments. The field of cardiomyopathy is at an exciting juncture with ongoing research.

In JACC's inaugural Behind the Science episode, Adith Arun, sits down with senior author Barry A. Borlaug, MD, to discuss his latest study published in JACC's December 16, 2025 issue, examining tricuspid regurgitation (TR) across the full spectrum of HFpEF. The study found that TR is common even in early HFpEF, with ventricular secondary TR (VSTR) representing the predominant pattern (≈26% vs. ≈8% ASTR). VSTR was closely associated with pulmonary vascular disease, greater right atrial enlargement, and significantly higher risks of HF hospitalization and mortality. The study also highlighted the limitations of using atrial fibrillation to define ASTR—nearly 46% of patients categorized as ASTR had no prior AFib. Importantly, clinically meaningful TR was observed even in exercise-only HFpEF, reinforcing the value of exercise hemodynamic testing for earlier detection.

Join JACC Associate Editor Emily Bucholz, MD, PhD, MPH, and author Rebecca Josowitz, MD, PhD as they discuss key findings from this JACC paper on placental malperfusion in congenital heart disease (CHD). The paper, published in JACC's November 11 issue, highlights future research directions, including identifying at-risk populations, developing imaging and molecular biomarkers, and exploring potential in utero therapies. This brief interview offers a compelling look at the intersection of fetal cardiology and placental biology. 

JACC continues its partnership with TCT 2025 in our latest interview, featuring JACC: Associate Editor Yousif Ahmad, MBBS, PhD, and author Shamir R. Mehta, MD, MSc. Listen here as they discuss this randomized, double-blind trial presented at TCT 2025 and published in JACC. Mehta et al demonstrate that intracoronary low-dose alteplase did not improve outcomes in STEMI patients with large thrombus burden and may increase arrhythmic risk. Together with prior studies, STRIVE closes the chapter on adjunctive intracoronary fibrinolysis as a strategy to improve outcomes during primary PCI.

JACC is proud to present research from the PROCTOR trial, and in this video interview with JACC Associate Editor Yousif Ahmad, MD and author Ruben W. de Winter, MD, review the randomized study comparing PCI of native coronary arteries versus saphenous vein grafts in patients with prior CABG. Contrary to expectations, the trial found that at one year, patients treated with vein graft PCI had significantly lower rates of major adverse cardiovascular events than those treated with native vessel PCI, challenging current guideline recommendations and highlighting the need for longer-term follow-up.

JACC continues its collaboration with TCT 2025 in this interview featuring JACC Associate Editor Celina M. Yong, MD, MBA, MSc, FACC, and lead investigator Professor Chao Gao, MD, PhD. The discussion spotlights the 3-year results of the REC-CAGEFREE I randomized trial comparing drug-coated balloons (DCB) with drug-eluting stents (DES) for de novo coronary lesions. Published in JACC and presented at TCT 2025, the findings reveal that while DCBs remained inferior to DES at 3 years, the outcome gap narrowed over time, primarily driven by elective revascularizations rather than death or MI. Professor Gao also explores bleeding risk, antiplatelet therapy patterns, bailout stenting rates, and where DCBs may find their optimal role, particularly in small vessel disease and high bleeding-risk patients.

In this episode, Dr. Makoto Mori, Associate Editor at JACC and Assistant Professor of Cardiac Surgery at Yale, interviews Dr. Paul Sorajja, lead author of the SUMMIT MAC Trial. They discuss the groundbreaking results of this study, which explores the use of the Tendyne transcatheter mitral valve replacement (TMVR) device in patients with severe mitral annular calcification (MAC)—a group traditionally challenging to treat surgically. Dr. Sorajja shares key findings, including high technical success rates, effective screening protocols, and significant improvements in patient outcomes. This conversation highlights a major advancement in structural heart disease treatment and its implications for clinical practice.

JACC's November 4 issue features the High Blood Pressure Guideline surrounded by a series of expert commentaries. In this video interview, JACC Deputy Editor Erica S. Spatz, MD, FACC, speaks with author Anand Vaidya, MD MMSc. Listen in for an insider view of the evolving understanding of primary aldosteronism in light of the 2025 high blood pressure guidelines. Dr. Vaidya emphasizes that primary aldosteronism may be a common, modifiable contributor to hypertension—potentially affecting up to 25% of patients—and advocates for simplified diagnostic approaches and broader use of mineralocorticoid receptor antagonists to improve outcomes.

The High Blood Pressure Guideline is paired with expert commentaries in JACC's November 4 issue. In this video interview focusing on one of the commentaries,  JACC Deputy Editor Erica S. Spatz, MD, FACC, talks with author Daichi Shimbo, MD, about the importance of out-of-office blood pressure monitoring. They discuss the latest guidelines, which give home and ambulatory monitoring the highest recommendation, and explore practical strategies for implementation, including validated devices, patient education, and data integration into clinical workflows.

JACC continues to provide context and highlight important content for readers, and our November 4 issue features the High Blood Pressure Guideline surrounded by a series of expert commentaries. In this video interview discussing the commentary on preeclampsia,  JACC Deputy Editor Erica S. Spatz, MD, FACC, speaks with author Vesna D. Garovic, MD, PhD about the complexities of hypertensive disorders in pregnancy, particularly preeclampsia. Dr. Garovic emphasizes the heterogeneity of preeclampsia, the need for earlier and more nuanced blood pressure management, and the importance of postpartum follow-up to mitigate long-term cardiovascular and renal risks for women.

JACC is pleased to bring readers several studies and presentations for TCT 2025 this year. In this interview, JACC Senior Advisor. David J. Cohen, MD and Mark A. Hlatky, MD, discuss the cost-effectiveness analysis conducted alongside the FAME 3 trial, comparing PCI guided by fractional flow reserve with CABG. They conclude that while both procedures yield similar long-term clinical outcomes, PCI is significantly less expensive—making it the economically favorable option for patients with equipoise in treatment choice.

Heart failure with preserved ejection fraction (HFpEF) has long lacked a unifying biological explanation—until now. In this presentation, Dr. Milton Packer introduces The Adipokine Hypothesis, a new framework that links visceral adiposity to the onset and progression of HFpEF through endocrine signaling between adipose tissue and the heart. Dr. Packer describes how visceral fat acts as an active endocrine organ, releasing adipokines that influence inflammation, fibrosis, and cardiac remodeling. He explains the roles of three major adipokine domains - protective, compensatory, and pathological—and how imbalances between them drive disease development.

In this JACC interview, JACC Executive Associate Editor Karthik Murugiah, MD, FACC, speaks with lead author Fabrizio D'Ascenzo, MD, PhD, as they review the randomized, multicenter PULSE trial. In the study (606 patients with unprotected left main PCI), routine 6-month CCTA surveillance did not lower the 18-month composite of death, myocardial infarction, unstable angina, or stent thrombosis compared with symptom-based follow-up. CCTA was associated with a lower rate of spontaneous MI (0.9 % vs 4.9 %) and more imaging-guided revascularizations (4.9 % vs 0.3 %). These findings suggest routine CCTA may not be necessary for all patients, but targeted use could inform earlier intervention. Additionally, the trial was powered for large risk reduction; thus, smaller but clinically meaningful benefits could still exist but remain undetected. This study is presented at ESC as a late-breaking clinical trial and simultaneously published in JACC.

JACC covers the latest science at ESC 2025 in this video interview with Neha J Pagidipati, MD, FACC and Stephen J. Nicholls, MBBS, PhD, FACC. The study, published in JACC and presented at ESC, discusses obicetrapib, a highly selective cholesteryl ester transfer protein inhibitor which lowers LDL-C and Lp(a) and raises HDL-C. This pooled analysis of trials investigating the lipid effects of 12 months of treatment with obicetrapib in patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia examined its effects on cardiovascular events. A lower rate of coronary heart disease death, myocardial infarction and coronary revascularization was observed with obicetrapib. Achieved levels of LDL-C, apoB, HDL-C, non-HDL-C and Lp(a) associated with the rate of cardiovascular events, requiring further exploration. This highlights the potential of obicetrapib to reduce cardiovascular risk.

Join Milton Packer, MD, FACC as he introduces the Adipokine Hypothesis—a groundbreaking framework for understanding heart failure with preserved ejection fraction (HFpEF). Drawing on decades of research, he explains how excess visceral adiposity alters adipokine biology, shifting from cardioprotective to pro-inflammatory signaling. This shift drives hypertrophy, inflammation, fibrosis, and ultimately HFpEF. Dr. Packer highlights striking parallels between obesity and HFpEF, reviews experimental and clinical evidence, and discusses how therapies—ranging from bariatric surgery to GLP-1 receptor agonists and SGLT2 inhibitors—restore adipokine balance and improve outcomes. Tune in for a thought-provoking exploration of how fat functions as the largest endocrine organ in the body and why it may hold the key to preventing and treating HFpEF.

JACC Associate Editor Michelle Kittleson, MD, PhD, speaks with author and ESC presenter Milind Desai, MBA. In this video interview related to the ODYSSEY-HCM trials presented at ESC, they discuss key findings published in JACC. The studies reveal promising insights into echocardiographic and biomarker changes, and long-term outcomes in asymptomatic HCM patients. Tune in for expert perspectives on how these results could shape future research and clinical care.

JACC is proud to publish this video interview with Associate Editor Jason H. Wasfy, MD, MPhil, FACC and Kristoffer Grundtvig Skaarup, MD. In their talk about this paper presented at ESC and simultaneously published in JACC, they discuss this exploratory prespecified analysis of the DAN-RSV Trial. RSVpreF vaccination was associated with reduced risks of RSV-related, respiratory, and cardio-respiratory hospitalizations, with no appreciable differences between individuals with and without HF and across HF subgroups.

JACC's latest research presented at ESC is reviewed here, with JACC: Associate Editor Theresa McDonagh, Bsc, MB ChB, MD speaking with co-authors and ESC presenters John W. Ostrominski, MD and Muthiah Vaduganathan, MD MPH. Listen in as they discuss two synergistic studies presented at ESC and simultaneously published in JACC. Both papers emphasize that BMI alone underestimates obesity prevalence and risk in heart failure and cardiometabolic patients, advocating for broader adiposity measures like waist circumference and waist-to-height ratio to improve risk stratification and treatment outcomes.

In this JACC interview, Michael Honigberg, MD, MPP joins Mitsuaki Sawano, MD, PhD, to discuss two simultaneous publications presented at ESC 2025 on the role of clonal hematopoiesis of indeterminate potential (CHIP) in cardiovascular disease. They highlight findings from the Women's Health Initiative Long Life Study, which examined CHIP in older women and revealed gene-specific risks (TET2, JAK2, ASXL1) linked to heart failure, coronary heart disease, and thromboembolism. They also review results from the LoDoCo2 trial substudy, showing how colchicine may blunt CHIP clonal growth—particularly TET2 mutations—and reduce IL-6 inflammation, suggesting new avenues for targeted prevention. The discussion concludes with a forward-looking perspective on the future of CHIP research, its therapeutic implications, and its potential to transform cardiovascular clinical practice.